Corbus Pharmaceuticals Holdings, Inc./$CRBP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Ticker
$CRBP
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
28
ISIN
US21833P3010
Website
CRBP Metrics
BasicAdvanced
$92M
-
-$4.23
3.20
-
Price and volume
Market cap
$92M
Beta
3.2
52-week high
$8.73
52-week low
$4.64
Average daily volume
139K
Financial strength
Current ratio
11.821
Quick ratio
11.522
Long term debt to equity
0.948
Total debt to equity
2.246
Interest coverage (TTM)
-55.91%
Management effectiveness
Return on assets (TTM)
-27.17%
Return on equity (TTM)
-44.89%
Valuation
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-1.784
Growth
Earnings per share change (TTM)
-32.84%
3-year earnings per share growth (CAGR)
-23.26%
CRBP News
AllArticlesVideos
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
GlobeNewsWire·1 day ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
GlobeNewsWire·4 days ago
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Corbus Pharmaceuticals Holdings, Inc. stock?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a market cap of $92M as of May 23, 2025.
What is the P/E ratio for Corbus Pharmaceuticals Holdings, Inc. stock?
The price to earnings (P/E) ratio for Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock is 0 as of May 23, 2025.
Does Corbus Pharmaceuticals Holdings, Inc. stock pay dividends?
No, Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Corbus Pharmaceuticals Holdings, Inc. dividend payment date?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock does not pay dividends to its shareholders.
What is the beta indicator for Corbus Pharmaceuticals Holdings, Inc.?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a beta rating of 3.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.